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Introduction
Cyclooxigenase (COX), also known as prostaglandin-
endoperoxide synthase (PTGS), is the rate-limiting
enzyme that catalyses the first step in prostaglandin
(PG) biosynthesis and acts both as a dioxygenase and
as a peroxidase. It catalyses the conversion of arachi-
donic acid (AA) to the key upstream prostanoid pre-
cursor prostaglandin H2 (PGH2) which is metabolised
into the prostaglandin isoforms PGE2, PGD2, PGF2,
PGI2,  or thromboxane A2 (TXA2).
Two isoforms of COX have been identified: the
constitutive COX-1 and the inducible COX-2, which
differ in the regulation of their expression and tissue
distribution [1].
COX-1 is constitutively expressed in a broad range
of cells and tissues where it mediates the synthesis of
PGs required for physiological functions. COX-1 reg-
ulates angiogenesis, it is also thought to be involved in
cell-cell signaling and in the maintenance of tissue
homeostasis. 
COX-2 is normally undetectable in most tissues,
although there are some exceptions, for example seminal
vesicles, kidney and regions of the central nervous sys-
tem (hippocampus, hypothalamus and spinal cord) con-
tain constitutively high levels of COX-2. COX-2 is rap-
idly induced by various mitogenic stimuli and proin-
flammatory agents including cytokines and endotoxin
[1-3]. COX-2 is expressed in a limited number of cell
types and is regulated by specific stimulatory events,
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suggesting that it is responsible for the prostanoid
biosynthesis required for inflammation and mitogenesis. 
Recently, over-expression of COX-2 was observed
in a variety of human malignancies, including colonic,
gastric, breast, esophageal, bronchial, prostatic carci-
nomas, and oral cancer [4-10]. Many studies indicated
that COX-2 contributes to tumorigenesis and to the
development of malignant phenotype through several
mechanisms, such as (1) inhibition of apoptosis; (2)
increased angiogenesis; (3) increased invasiveness; (4)
modulation of inflammation/immuno-suppression; and
(5) stimulation of cell proliferation [11-13].
Inflammation is a non-specific immune response to
infection, irritation or other injury, it is characterized
by redness, swelling, pain, and loss of function. When
harmful agents invade the human body, inflammatory
mediators are released by immune cells, this release
causes vasodilatation, migration of neutrophils,
chemotaxis and increased vascular permeability. Two
separate pathways produce inflammatory mediators:
one is initiated by COX-2 and produces PGs, while the
other is initiated by 5-Lypoxigenase (5-LOX) and pro-
duces LTs, PGE2, LTA4 and LTB4 [14-17].
The oral cavity is exposed to chronic or recurrent,
physical and chemical trauma that could lead to
mucosal reactions such as hyperplasia, dysplasia and
cancer. Early diagnosis has been indicated as the most
important issue to address in the prevention of oral
cancer, but the diagnosis of oral cancer at an early
stage is made obstructed by the difficulty in differen-
ciating premalignant and malignant lesions from simi-
lar-looking benign lesions. Early-stage oral cancers are
asymptomatic, furthermore, they often appear innocu-
ous, since the classic clinical features associated with
advanced oral cancers, including ulceration, indura-
tion, elevation, bleeding and cervical adenopathy usu-
ally are absent in early stage lesions. 
Early diagnosis of precancerous oral lesions can
have an important impact on oral cancer mortality
rates. To this aim it could be useful to identify molec-
ular markers whose expression is associated with the
various stages of oral cancer progression.
In previous works we studied the expression of
remodelling enzymes, such as metalloproteinases
(MMPs) 2 and 9, in normal and pathological oral
mucosa investigating the relationship between the
level of expression of MMPs and the progression of
oral mucosa pathological conditions towards the
malignant phenotype [18-19]. Since COX enzyme
has been involved, with various mechanisms, in the
development of malignancies, in this work we inves-
tigated the expression and  localization of COX-1
and COX-2 in normal human oral mucosa and three
different pathological conditions (hyperplasia, dys-
plasia and carcinoma) by immunohistochemistry and
RT-PCR.    
Materials and methods
Samples. The samples used in this study were provided by the
odontostomatological clinic of the University hospital "Paolo
Giaccone" in Palermo and include: 9 normal oral mucosa, 13 cases
of hyperplasia, 8 cases of dysplasia and 7 cases of carcinoma (4
cases of squamous cell carcinoma of the oral mucosa and 3 cases
of squamous cell carcinoma of the tongue). 
With the term hyperplasia we mean a pathological condition
characterized by a hyperproliferation of normal cells, while for
dysplasia we refer to a pathology characterized by disorganized
hyperproliferation of cells that present some grade of atypia and
leads to altered tissue morphology, it is a pre-cancerous lesion that
can regress or evolve toward a cancer. In the carcinoma group we
include malignant tumors of epithelial origin.
Immunohistochemistry. Samples were dissected and fixed in for-
malin solution. After fixation the tissue was dehydrated in a series of
alcohols, cleared in xylene and paraffin embedded. Section of 7μm
were cut with a Leica microtome RM2145, dried overnight at 37°C
and then stored at room temperature until use. On the day of the
experiment slides were dewaxed in xylene and rehydrated in a series
of alcohols. Slides were then transferred into distilled water for 5 min. 
The immunohistochemistry was performed using the
"DakoCytomation EnVision + System-HRP (AEC)" kit from Dako
(Dako, Glostrup Denmark), following the manufacturer's instruc-
tions. Briefly: sections were incubated with the "Peroxidase block"
reagent for 5 min at room temperature. The samples were rinsed
once in PBS (Phosphate Buffer Saline) pH 7.2. The sections were
covered with antibody solution and incubated at 4°C overnight.
Monoclonal mouse anti human COX-1 antibody (ZyMed Labo-
ratories, Invitrogen immunodetection) (1:50 dilution), monoclonal
mouse anti human COX-2 (DakoCytomation) (1:100 dilution) were
used. As negative controls for our antibodies we used mouse IgG1
antibody (Dako, clone DAK-G01) (1:100 dilution). All antibodies
were diluted in a 0.1% Bovine Serum Albumine (BSA) solution. 
Human seminal vesicles and human epididymis were used
respectively as positive control samples for COX-2 and COX-1
antibodies since these proteins are constitutively expressed in these
tissues.
Samples were rinsed twice in PBS pH 7.2 and then incubated
for 30 min. with the "Peroxidase Labelled Polymer" reagent. Sam-
ples were rinsed twice in PBS pH 7.2. They were then incubated
for 4 min. with the "Substrate-Chromogen" reagent. The staining
procedure was identical for all the samples. The same incubation
time with the chromogen reagent was used for all the samples.
Reaction was stopped by rinsing the slides in distilled water.
A negative control sample was treated in an identical manner
but the primary antibody was omitted. Slides were coverslipped
using the "DakoCytomation Faramount Aqueous Mounting Medi-
um" from Dako (Dako, Glostrup Denmark). The specimens were
observed under a Leica DM1000 light microscope.
Semi-quantitative evaluation of immunoreactivity. The intensity
of immunostaining for COX-1 and COX-2 in our specimens was
evaluated by three independent observers according to the following
criteria: (0) no staining, (1) light staining, (2) moderate staining, (3)
intense staining. Statistical analysis of data was performed by the chi-
square test, and P-value less than 0.05 was taken to be significant.
Total RNA extraction. Samples were frozen in liquid nitrogen
immediately after surgical dissection and stored at -80°C until use.
Total RNA extraction was accomplished using the "illustra
RNAspin Mini Kit" (Amersham Biosciences, Milan, Italy) follow-
ing the manufacturer's instructions. RNA yield was evaluated spec-
trophotometrically (A260/A280) and RNA aliquots were stored at
-80°C until use. 
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Reverse-Transcription (RT) – Polymerase Chain Reaction
(PCR). For RT reaction 2 μg RNA was used. To avoid DNA con-
tamination in the RNA samples DNAse digestion was performed
using "AMPD1 kit" (SIGMA). RT reaction was performed using the
"Enhanced avian HS RT-PCR kit" (SIGMA) following the manufac-
turer's instructions. Briefly: 1μl random nonamers and 1 μl anchored
oligo (dT)23  were added to the DNAse digestion product and incu-
bated at 70°C for 10 min to denature the sample. Then 2 μl 10× Buf-
fer, 1 μl deoxynucleotide mix, 1 μl RNAse inhibitor, 1 μl Enhanced
AMV Reverse Transcriptase enzyme and DEPC water were added to
the sample. The RT reaction was performed in 20 μl total volume at
42°C for 50 min, followed by 95°C for 5 min to inactivate the
enzyme. The PCR was performed using the "PCR enzyme Selection
Kit – High specificity" (Invitrogen) following the manufacturer's
instructions. Briefly: 2 μl of template DNA, 0.5 μl of the Primers
mix (200 nM final concentration) and 22.5 μl of the "Platinum Super
Mix" were mixed together. The reaction was initially cycled at 94°C
for 3 min. It then underwent 40 cycles at 94°C for 60 sec, at 56°C
for 60 sec, at 72°C for 60 sec, with a final extension at 72°C for 10
minutes. GAPDH (GlycerAldeyde 3-Phosphate DeHydrogenase)
gene was used as internal positive control. Primers sequences are
listed in table 1. PCR products were visualized on 2% agarose gels,
stained with SYBR GREEN, observed with a transilluminator and
photographed with a digital camera.
Ethical issues. Informed consent was obtained from the patients a
pre-surgery. The experimentation was approved by the ethics com-
mittee.
Results
Immunohistochemical analysis of normal oral mucosa
showed a very low immunoexpression for COX-1 in
the epithelial region (Fig. 1A), while it did not show
immunoreactivity for COX-2 (Fig. 2A). RT-PCR
analysis performed on normal oral mucosa confirmed
this data showing COX-1 mRNA transcription but not
COX-2 (Fig. 3).
All hyperplasia samples showed COX-1 expression
in mucosal epithelium (Fig. 1B) and vessel endotheli-
um (Fig. 1C) and COX-1  immunoreactivity was sig-
nificantly higher compared to control (p<0.05) (Chart
1). Some of hyperplasia samples showed a weak COX-
2 expression in epithelium and vessel endothelium
(Figs. 2B, 2C) showing the same spatial distribution as
COX-1. Immunohistochemical data were confirmed
by RT-PCR analysis; COX-1 mRNA was detected in
all hyperplasia samples, while only part of the samples
expressed COX-2 mRNA.
All dysplasia samples expressed both COX-1 (Figs.
1D and 1E) and COX-2 proteins (Figs. 2D, 2E). For
both protein expression was localised in the cytoplasm
of the cells and a clear zone was evident in the nuclear
region. COX-1 immunoreactivity was more intense
than hyperplasia samples and was localized in epithe-
lium and around vessel walls. COX-2 expression was
significantly higher than hyperplasia (p<0.05). RT-
PCR analysis confirmed these data showing mRNA
transcription for both genes; in figure 4 is evident an
intense expression of both COX-1 and COX-2 even
compared to the control gene GAPDH.
All carcinoma samples showed COX-1 expression,
immunoreactivity was stronger than all the other normal
and pathological samples examined (Fig.1F) and this
increase was statistically significant (p<0.05). COX-2
protein was expressed only in some of carcinoma and
immunostaining was not intense as in dysplasia (Fig.
2F). RT-PCR analysis was in agreement with immuno-
histochemical data, showing an intense COX-1 mRNA
expression in all carcinomas and a moderate COX-2
mRNA presence in some of the samples.
Immunohistochemistry showed a progressive
increase of COX-1 protein expression from normal
oral mucosa towards hyperplasia, dysplasia and final-
ly carcinoma (Chart 1). On the contrary, semi-quanti-
tative RT-PCR analysis showed a quite constant level
of expression for COX-1 mRNA in normal samples,
hyperplasia and dysplasia and an increase of COX-1
gene expression only in carcinoma. 
Both immunohistochemistry and RT-PCR analysis
gave the same results for COX-2 trend: COX-2 expres-
sion was not detected in normal oral mucosa samples,
while a moderate expression was found in hyperplasia.
The maximum COX-2 mRNA and protein levels were
detected in dysplasia samples, while carcinoma shows
a slight reduction of COX-2 expression (Chart 1).
Discussion  
COX is the key-enzyme catalysing the first step in the
biosynthesis of prostaglandins, molecules that play 
a pivotal role in the initiation and progression of
many cancers. In particular COX-2 seems to act syn-
ergistically with cytosolic phospholipase A2, the
Table 1. Name, sequence and amplification product size of the primers used in this study.
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other key enzyme of prostaglandin synthesis, to con-
tribute to the process of oral carcinogenesis and both
enzymes are overexpressed in oral dysplasia and car-
cinoma [8].
Overexpression of COX-2 is reported in many can-
cers and selective COX-2 inhibitors are known to 
suppress cell proliferation by inducing G0/G1 phase, cell
cycle arrest and apoptosis [13,20-21]. 
Fig. 1. COX-1 immunohistochemistry in human oral mucosa samples. (A) Light immunostaining for COX-1 in the epithelium of normal
oral mucosa (original magnification ×100); (B) Hyperplasia: COX-1 expression in epithelium and many cells of connective tissue (orig-
inal magnification ×20); (C) Hyperplasia: COX-1 in vessel endothelium (original magnification ×40); (D-E) Dysplasia: COX-1 expres-
sion in the cytoplasm of epithelial cells (original magnification ×20, ×40); (F) Carcinoma: very strong COX-1 expression in some cells
of the superficial epithelial layers (original magnification ×100).
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The contribution of COX to carcinogenesis is due
to its involvement in several key-mechanisms: 1) the
conversion of pro-carcinogens to carcinogens as a
consequence of arachidonic acid metabolism, 2)
stimulation of cell growth, 3) inhibition of apoptosis
through P53 suppression and Bcl2 induction, 4) stim-
ulation of VEGF and angiogenesis, 5) promotion of
invasion and metastasis via matrix metalloproteinases
Fig. 2. COX-2 immunohistochemistry in human oral mucosa samples. (A) Normal oral mucosa: no COX-2 immunostaining; (B) Hyper-
plasia: light COX-2 expression in epithelium (original magnification ×40); (C) Hyperplasia: light COX-2 expression in endothelium
(original magnification ×100); (D-E) Dysplasia: strong COX-2 immuno-expression in epithelium (original magnification ×40, ×20); 
(F) Carcinoma: COX-2 in the cytoplasm of epithelial cells (original magnification ×40).
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induction, 6) immunosuppression by IL-10 induction
[12-13,22-23]. 
As it is well known, COX-2 is probably one of the
most important agents involved in the development
and evolution of inflammation. Long term use of drugs
that inhibit COX activity, such as aspirin or non-
steroidal anti-inflammatory drugs (NSAID), is associ-
ated with 30-50% reduction in risk of colorectal,
esophagus, stomach, breast, lung, prostate, urinary
bladder and ovary cancer. The fact that chronic or
acute inflammation is commonly associated with can-
cer complicates the interpretation of COX-2 expres-
sion in cancer. On one hand, the tissue disruption and
cell death typical of cancer recruit pro-inflammatory
cells and lead to inflammation. On the other hand,
some types of chronic inflammation are the cause of
the initiation of certain cancers, such as chronic hepa-
titis, chronic gastritis and chronic ulcerative colitis.
Thus it may be very difficult to separate COX-2
expression related to inflammation from that related to
tumor transformation [24].
Inflammation is the main etyological factor in oral
squamous cell carcinoma (OSCC), COX-2 activity is
related both to inflammation and carcinogenesis and
its expression has been found increased in OSCC
together with other pro-inflammatory molecules as
inducible nitric oxide synthase (iNOS) and vascular
endothelial growth factor (VEGF); overexpression of
these markers was also associated with limph node
metastasis, tumor staging and grading [25-26]. 
Cohesive scientific evidence from molecular, ani-
mal, and human investigations support the hypothesis
that aberrant induction of COX-2 and up-regulation of
the prostaglandin cascade play a significant role in
carcinogenesis. Blockade of these processes has strong
potential for cancer prevention and therapy [12,22,26]. 
The hypothesis of COX involvement in cancer
progression has been strengthened by the effect of
COX inhibitors that have been successfully used in
the treatment of many cancers [27-31]. The efficacy
of COX selective and nonselective inhibitors against
oral carcinogenesis has been confirmed by in vitro
and in vivo studies on rat: COX inhibitors showed to
be chemopreventive agent decreasing oral cancer
incidence, cell growth, proliferation of xenografted
tumors, cancer invasion score and cancer-related
mortality [10,32]. The mechanism responsible for
these effects is still unclear, but some of the studies
indicated a possible involvement of matrix metallo-
proteinases (MMPs) in this mechanism: COX inhibi-
tion suppresses the invasiveness of oral squamous
cell carcinoma via down-regulation of MMP-2 activ-
ity [33-34]. Even if COX inhibitors are promising
candidates for cancer therapy it is to consider the
emerging side-effects of these drugs, above all the
cardiovascular risk associated with the use of these
compounds [12,27]. 
Fig. 5. Semi-quantitative analysis of COX-1 and COX-2
immunoreactivity in the samples. Bars represents the mean stan-
dard deviation.
Fig. 3. Representative picture of RT-PCR analysis in normal oral
mucosa sample. Lane 1: GAPDH amplification product (232 bp);
lane 2: 100 bp DNA ladder; lane 3: no amplification product for
COX-2 gene; lane 4: COX-1 amplification product (319 bp).
Fig. 4. Representative picture of RT-PCR analysis in dysplasia
sample. Lane 1: COX-1 amplification product (319 bp); lane 2:
COX-2 amplification product (196 bp); lane 3: 100bp DNA ladder;
lane 4: GAPDH amplification product (232 bp). 
The use of COX inhibitors in treatment of cancer
has given good results especially in combination with
other conventional cancer therapy. The combination of
COX inhibitors with chemotherapy or radiotherapy
has shown synergistic effects on tumor growth and
development both in vitro and in vivo [35-36]. Also
the combination with EGFR inhibitor resulted in
almost complete inhibition of tumor growth [37-38]. 
While the overexpression of COX-2 in oral cancer
has been widely reported and is generally accepted by
the scientific community, there are contrasting opin-
ions on the possibility that COX-2 expression could be
used as a prognostic tool to predict the outcome of the
disease; some author report a correlation between
COX-2 overexpression and poor prognosis [39] while
others don't [40]. Moreover, opinions regarding the
correlation between COX-2 expression and the histo-
logic grade of oral cancer are highly conflicting; many
authors report a progressive increase of COX-2
expression from normal oral mucosa towards invasive
carcinoma [39,41-43], others report an higher COX-2
expression in premalignant lesion than in malignancies
[4,6,44-45], while others report the lack of correlation
between COX-2  level and tumor stage or grade [7,46]. 
Another confounding factor is the wide variability
of COX-2 expression observed in different individuals
in the same pathological condition, this heterogeneity
has been attributed to the difference in oral mucosa
microenvironment, evolutive stage of the tumor, etio-
logic factors and gene mutations.  
In this study we examined the following three patho-
logical conditions: hyperplasia, dysplasia and carcino-
ma, as sequential steps in the process of cancer progres-
sion towards the malignant phenotype. This approach
can help understanding the development of tumor trans-
formation from normal oral mucosa to oral cancer. 
By immunohistochemistry we detected a progres-
sive increase of COX-1 protein expression from nor-
mal oral mucosa towards hyperplasia, dysplasia and
finally carcinoma; this increase parallels the severity
of the lesion. On the contrary, RT-PCR analysis
showed a quite constant level of COX-1 mRNA in nor-
mal samples, hyperplasia and dysplasia and an
increase of COX-1 gene expression only in carcinoma. 
These data suggest that the progressive increase of
COX-1 enzyme detected through immunohistochem-
istry is due more to regulation of protein synthesis
(translation) than regulation of gene expression (tran-
scription). This means that the level of COX-1 gene
expression in control, hyperplasia and dysplasia
remains constant while the rate of protein synthesis
can vary in relation with the transition from a physio-
logical to a pathological condition. Finally in the last
step of the transition to carcinoma the increase of
COX-1 gene expression parallels the increase of pro-
tein expression.
Both immunohistochemistry and RT-PCR analysis
gave the same results for COX-2 trend; COX-2
expression was not detected in normal oral mucosa,
while a moderate expression was found in hyperplasia.
The maximum COX-2 mRNA and protein levels were
detected in dysplasia samples, while carcinoma
showed a light reduction of COX-2 expression com-
pared to dysplasia.
Our data are in agreement with all the studies
[4,5,7,23-24] that report a higher expression of COX-
2 in precancerous lesions than in malignancies and that
hypothesize a correlation between COX-2 activation
and the early stages of carcinogenesis.
We believe that COX-2 activity could be involved
in the initial phases of the process of tumor transfor-
mation. We hypothesize that COX-2 gene and protein
expression, that is absent in normal cells, is required
during the early stages of carcinogenesis. They are
switched on during hyperplasia (with some of the sam-
ples moderately expressing COX-2) and are fully acti-
vated during dysplasia (with all the samples clearly
expressing COX-2). Later on, in more advanced stages
of tumor development such as carcinoma, when the
tumor is well established, the involvement of COX-2
activity could be less critical and for this reason COX-
2 starts to be down-regulated (with only part of the
samples still expressing COX-2).
In a previous study [19] we investigated the expres-
sion of the metalloproteinases MMP-2 and MMP-9 in
normal oral mucosa and in the same three pathological
conditions we refer in this work. We detected a pro-
gressive increase of MMPs mRNA and protein expres-
sion from normal oral mucosa to hyperplasia, dyspla-
sia and carcinoma, finding a correlation between
MMPs overexpression and the development of a
malignant phenotype. 
Starting from these data we moved our attention on
COX-1 and COX-2 expression in tumor development.
These two classes of enzymes (metalloproteinases and
cycloxigenases) are both involved in phenomena relat-
ed to inflammation, atherosclerosis, angiogenesis, can-
cer progression and invasiveness, and both are de-reg-
ulated in many types of tumor. Some studies indicated
a possible involvement of MMPs in the control of can-
cer progression dependent by COX inhibitors [33-34].
So we thought it could be appropriate to consider these
enzymes as if they were functionally correlated  and
study them in parallel. 
Comparing the expression of MMPs and COXs in
the samples examinated we found that COX-1 expres-
sion parallel that of MMP-2 and 9, increasing from
normal oral mucosa towards carcinoma, while COX-2
does not follow the same trend, reaching its maximum
expression in pre-cancerous conditions (dysplasia).
We hypothesize that extracellular matrix remod-
elling due to MMPs activity is a factor necessary for
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tumor establishment and progression, thus the
increase of MMPs expression is maintained till the
last steps of carcinogenesis. On the other hand,
COX-2 pro-inflammatory activity, however, could
be more involved in pre-cancerous conditions than in
established tumor, so COX-2 over-expression can be
more significant in dysplasia than in carcinoma.
Finally the fact that COX-1 is inducible under
inflammatory condition [21] could explain the pro-
gressive COX-1 increase we detected in the patholo-
gies investigated.
This study, and further more, could contribute to the
early diagnosis of oral cancer and to the  development of
new therapies based on cyclooxigenases inhibitors.
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